Back to search results

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Abroad (travel likely)RecruitingPHASE1

Conditions

Refractory Non-Hodgkin Lymphoma · Burkitt Lymphoma · Mantle Cell Lymphoma · Follicular Lymphoma · Lymphoplasmacytic Lymphoma · Primary Mediastinal Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma · Small Lymphocytic Lymphoma · Transformed Lymphoma · Non-Hodgkin Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of California, San Francisco, San Francisco, California, United States

    Contact: Study coordinator (UCSF HDFCCC Cancer Immunotherapy Program) · HDFCCC.CIP@ucsf.edu · 877-827-3222
    Study coordinator · cancertrials@ucsf.edu
    C. Babis Andreadis, MD (Sub-investigator)
    Contact: Principal Investigator (Carrie Ho, MD)
Study leads

  • Carrie Ho, MD

    Principal Investigator

    University of California, San Francisco

View source on ClinicalTrials.gov(opens in a new tab)